On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, Gardasil.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

1036 ET – Merck’s struggles with Gardasil aren’t easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to $ ...